На этой странице перечислены больницы направления «Медицинская онкология» (включая CAR T-Cell Therapy) в Дубай, ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.
Спросите нас о «CAR T-Cell Therapy» в Дубай, ОАЭ
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 3 аккредитованных больниц (Медицинская онкология) в Дубай, ОАЭ
🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
🇦🇪 Kings College Hospital Dubai
🇦🇪 Aster Hospital Dubai
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Медицинская онкология» указано среди её специализаций и она находится в Дубай, ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «car t-cell therapy» в Дубай, ОАЭ?
Выбор подходящей больницы для «car t-cell therapy» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Медицинская онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «CAR T-Cell Therapy»
CAR T-Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy) is a groundbreaking, personalized immunotherapy that genetically engineers a patient's own T-lymphocytes to recognize and destroy cancer cells with precision unmatched by conventional chemotherapy or radiation. In landmark clinical trials, CAR T-Cell products such as axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) have achieved complete remission rates of 40–54% in relapsed/refractory large B-cell lymphoma and up to 81% overall response rates in pediatric B-cell ALL. GAF Healthcare connects international patients with India's and the UAE's most advanced CAR T-Cell centers—offering JCI/NABH-accredited oncology programs, world-class apheresis infrastructure, and end-to-end logistics support at a fraction of Western costs.
Clinical Overview
CAR T-Cell Therapy represents a paradigm shift in the treatment of hematological malignancies and is increasingly being explored in solid tumors. The process begins with leukapheresis—collecting a patient's T-lymphocytes from peripheral blood—which are then sent to a Good Manufacturing Practice (GMP)-certified laboratory where they are retrovirally or lentivirally transduced to express a chimeric antigen receptor on their surface. This receptor is engineered to bind a specific tumor antigen (most commonly CD19 for B-cell malignancies, BCMA for multiple myeloma, or CD22 as an emerging target) with high affinity, bypassing the need for MHC-mediated antigen presentation that cancer cells frequently downregulate to evade immunity.
Подробнее →Who is a Candidate?
- ELIGIBLE DIAGNOSES: Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of systemic therapy; R/R follicular lymphoma (grade 3B); R/R mantle cell lymphoma; R/R B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and young adult patients (up to age 25); R/R multiple myeloma after ≥4 prior lines (including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody).
- PERFORMANCE STATUS: ECOG performance status 0–2; Karnofsky Performance Score ≥60%.
- ORGAN FUNCTION REQUIREMENTS (ELIGIBILITY THRESHOLD): Creatinine clearance ≥45 mL/min (CKD-EPI formula); ALT/AST ≤5× ULN; total bilirubin ≤2× ULN; LVEF ≥50% confirmed on 2D Echocardiography (ECHO) or MUGA scan; no active Grade ≥3 pulmonary dysfunction (baseline O₂ saturation ≥92% on room air).
- REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: Whole-body PET-CT scan (FDG) within 4 weeks; bilateral bone marrow biopsy with flow cytometry and cytogenetics; complete blood count with differential and comprehensive metabolic panel; serum protein electrophoresis and immunofixation (for myeloma); HLA typing (for allogeneic considerations); infectious disease panel (HIV Ag/Ab, Hepatitis B surface Ag and core Ab, Hepatitis C Ab, CMV IgG/IgM, EBV VCA IgG, quantitative CMV PCR); cardiac ECHO; pulmonary function tests (FEV1, DLCO); MRI brain (to rule out CNS disease or ICANS risk factors); prior treatment records including all chemotherapy regimens, radiation fields, stem cell transplant history.
- RELATIVE CONTRAINDICATIONS: Active, uncontrolled infection including active Hepatitis B replication (HBV DNA detectable); active CNS malignancy with mass lesion >1 cm (relative, not absolute); history of severe autoimmune disease requiring systemic immunosuppression; prior allogeneic HSCT within 6 months or active graft-versus-host disease (GVHD) on immunosuppression; active corticosteroid use (>10 mg prednisone/day equivalent) within 72 hours of infusion; pregnancy or lactation.
- +1 more
Treatment Options & Approaches
CAR T-Cell Therapy is not a single procedure but a multi-step biological manufacturing and clinical delivery process. The following approaches and product categories are available at partner centers in India and the UAE:
1. AUTOLOGOUS CAR T-CELL THERAPY (CURRENT STANDARD): The patient's own T-cells are harvested, engineered, and reinfused. Products include FDA/EMA-approved tisagenlecleucel (lentiviral CD19-targeting), axicabtagene ciloleucel (retroviral, CD19), lisocabtagene maraleucel (lentiviral, CD19, defined 4-1BB co-stimulatory domain with a 1:1 CD4:CD8 ratio for reduced neurotoxicity risk), brexucabtagene autoleucel (retroviral, CD19, specifically approved for mantle cell lymphoma), and BCMA-targeting constructs idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma. Manufacturing turnaround time ranges from 17 to 22 days for most commercial products.
2. LOCALLY MANUFACTURED / ACADEMIC CAR T-CELL PROGRAMS (INDIA-SPECIFIC): Several institutions in India—including Tata Memorial Centre (Mumbai), AIIMS (New Delhi), and Christian Medical College (Vellore)—have established indigenous CAR T-Cell manufacturing programs under the Central Drugs Standard Control Organisation (CDSCO) regulatory framework. India's first indigenously developed CD19 CAR T-Cell product (developed collaboratively by ACTREC and IIT Bombay) received CDSCO approval in 2023, at a significantly reduced cost compared to imported commercial products ($40,000–$70,000 vs. $350,000+ in Western markets). This is a critical cost advantage for international patients.
3. DUAL-ANTIGEN / BISPECIFIC CAR T-CELL CONSTRUCTS (INVESTIGATIONAL / CLINICAL TRIALS): Available at select academic centers; constructs targeting CD19/CD22 simultaneously are designed to overcome antigen escape—a primary mechanism of relapse after single-antigen CD19 CAR T-Cell therapy. Patients who have failed prior CD19 CAR T-Cell treatment may be eligible.
Подробнее →Восстановление
PHASE 1 — PRE-TRAVEL CONSULTATION (2–4 weeks before departure):
- Upload complete medical records, PET-CT, bone marrow biopsy, and prior treatment summaries to GAF Healthcare's secure patient portal.
- GAF's oncology case managers facilitate a teleconsultation with the destination center's CAR T-Cell specialist within 48–72 hours.
- Treatment eligibility is confirmed; manufacturing slot is reserved with the CAR T-Cell program.
- India: e-Medical Visa (e-MV) application assisted by GAF (processing 3–5 business days). UAE: Visa-on-arrival or visa waiver available for 50+ nationalities; GAF assists with medical invitation letter for others.
PHASE 2 — ARRIVAL & PRE-TREATMENT WORKUP (Days 1–5 in country):
Подробнее →Возможные риски
CAR T-Cell Therapy carries a distinct and serious toxicity profile that patients and caregivers must understand thoroughly before initiating treatment. Cytokine Release Syndrome (CRS) is the most common acute toxicity, occurring in 57–93% of patients depending on the product and disease burden; Grade 3–4 CRS (severe hypotension, Grade 3+ hypoxia requiring high-flow oxygen or mechanical ventilation) occurs in 13–22% of cases and requires ICU-level management including vasopressors and tocilizumab. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in 20–60% of patients, presenting as confusion, aphasia, tremor, and in severe cases (Grade 4), seizures, cerebral edema, and rarely death; the mortality risk from Grade 4 ICANS is approximately 1–3%. Prolonged and severe cytopenias (neutropenia, anemia, thrombocytopenia) lasting beyond 30 days occur in 30–40% of patients and substantially increase infection risk; febrile neutropenia requires prompt hospitalization and broad-spectrum antibiotics. B-cell aplasia is an expected on-target off-tumor effect of CD19 CAR T-Cell products and leads to hypogammaglobulinemia requiring monthly IVIG infusions, sometimes for 12–24 months post-treatment. Hemophagocytic lymphohistiocytosis (HLH) is a rare (2–5%) but life-threatening hyperinflammatory complication associated with a mortality rate of 30–50% if not recognized promptly; it is characterized by hyperferritinemia (>10,000 ng/mL), cytopenias, and liver dysfunction. Tumor lysis syndrome (TLS) can occur in the context of rapid disease response, particularly in high-burden lymphoma, and requires aggressive pre-infusion hydration and urate-lowering therapy (allopurinol or rasburicase). Late-onset infections—particularly with encapsulated bacteria, CMV reactivation, and opportunistic fungi—remain a risk during the 6–12 months of immune reconstitution. Disease relapse, occurring in 30–60% of responders within 2 years, may be mediated by antigen loss (CD19 downregulation), T-cell exhaustion, or immunosuppressive tumor microenvironment, and may require subsequent therapy. All patients must have a dedicated caregiver present 24 hours per day during the mandatory inpatient and early outpatient phases. Travel insurance must specifically cover CAR T-Cell-related complications; GAF Healthcare's partner insurance advisors assist with policy identification.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated, end-to-end logistics infrastructure designed specifically for the complexity of CAR T-Cell therapy, where timing, proximity to the treatment center, and rapid access to emergency care during the post-infusion monitoring period are non-negotiable.
Частые вопросы о процедуре «CAR T-Cell Therapy»
What is the cost of CAR T-Cell Therapy in India vs the UAE?
How long do I need to stay in the country before I am fit to fly home after CAR T-Cell Therapy?
What is the success rate of CAR T-Cell Therapy?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «car t-cell therapy» в Дубай, ОАЭ
Найдите лучшие больницы для «car t-cell therapy» в Дубай, ОАЭ
На этой странице представлено 3 больниц в Дубай, ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «CAR T-Cell Therapy» в Дубай, ОАЭ
Сколько больниц направления «Медицинская онкология» представлено в Дубай, ОАЭ?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дубай, ОАЭ?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «CAR T-Cell Therapy» в Дубай, ОАЭ.
Свяжитесь с нами, если заметите неточность на этой странице.